Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631462 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
A Phase 1 study of Myelofibrosis, sponsored by TargeGen.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 6
- Study locations
NCT00631462: Completed Phase 1 study of Myelofibrosis, sponsored by TargeGen.
NCT00631462 is a Phase 1 study of Myelofibrosis that has completed, run by TargeGen. The registered enrollment target is 59 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (70% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00631462, a Phase 1 study of Myelofibrosis, has completed, sponsored by TargeGen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
Conditions Studied
Interventions
- DRUG TG101348
Study Locations (6)
California
- UCSD Moores Cancer Center - San Diego
- Stanford Comprehensive Cancer Center - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Minnesota
- Mayo Clinic, Rochester - Rochester
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
What the finished NCT00631462 record still lists
NCT00631462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which TG101348 is the first listed.
NCT00631462 lists 6 locations in 5 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT00631462 about?
NCT00631462 is a clinical study titled "A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis". The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
What is the current status of trial NCT00631462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2008-01. Estimated completion is 2009-10.
What conditions does trial NCT00631462 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT00631462?
The interventions under investigation include: TG101348 (DRUG).
Who is sponsoring clinical trial NCT00631462?
This trial is sponsored by TargeGen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00631462 being conducted?
This trial has 6 study locations across California, Massachusetts, Michigan, Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00631462's enrollment target sits among peer trials
59 29th of 61 higher than 33 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia